Status:
COMPLETED
Famotidine Outpatient COVID-19 Treatment Study
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
Cold Spring Harbor Laboratory
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patient...
Detailed Description
Famotidine is a histamine-2 receptor antagonist, widely available over-the-counter, and is safely used for suppression of gastric acid production over a wide range of doses from 20mg once daily to 160...
Eligibility Criteria
Inclusion
- Age \>18 years; Ability to give written informed consent; Confirmed COVID-19 diagnosis; Famotidine use during COVID-19 illness
Exclusion
- none
Key Trial Info
Start Date :
May 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 25 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04389567
Start Date
May 12 2020
End Date
May 25 2020
Last Update
May 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York, United States, 11724